From remote sensing to relevant sensing in human health - Introduction by Hay, S, Myers, M, Maynard, N, Rogers, D

Quality control in upper gastrointestinal endoscopy: detection rates of gastric cancer in Oxford 2005-2008. by Vradelis, S, Maynard, N, Warren, B, Keshav, S, Travis, S

Consumer demand for Prize-Linked Savings: a preliminary analysis by Tufano, P, Maynard, N, De Neve, J

From remote sensing to relevant sensing in human health by Hay, S, Myers, M, Maynard, N, Rogers, D

Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics. by Findlay, J, Bradley, K, Gillies, R, Maynard, N, Middleton, M

Additional benefit of 18F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer by Gillies, R, Middleton, MR, Maynard, N, Bradley, K, Gleeson, F

Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer. by Gillies, R, Middleton, MR, Maynard, N, Bradley, K, Gleeson, F

EpCAM and gpA33 are markers of Barrett's metaplasia. by Wong, N, Warren, B, Piris, J, Maynard, N, Marshall, R, Bodmer, W

Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma. by Gillies, R, Middleton, MR, Han, C, Marshall, R, Maynard, N, Bradley, K, Gleeson, F

Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma by Gillies, R, Middleton, MR, Han, C, Marshall, R, Maynard, N, Bradley, K, Gleeson, F

Neoadjuvant chemotherapy for oesophageal carcinoma - a risk factor for postoperative pneumonia? by Millo, J, Tam, M, Grange, C, Sica, G, Salmon, J, Garrard, C, Maynard, N

Open left thoracoabdominal esophagectomy a viable option in the era of minimally invasive esophagectomy by Klevebro, F, Han, S, Ash, S, Mueller, C, Cools-Lartigue, J, Maynard, N, Ferri, L, Low, D

CALMS 2 protocol version 2.2 and patient information leaflet by Watkinson, P, Salmon, J, Young, D, Maynard, N, Tarassenko, L, Vollam, S, Evans, D, Saunders, T, Birks, J

Dashboarding for real-time analysis of oesophagogastric outcomes data by Ash, S, Antonowicz, S, Matarangolo, A, Menon, N, Owen, R, Gillies, R, Sgromo, B, Marshall, R, Maynard, N

Survival after curative chemoradiotherapy or neoadjuvant therapy and surgery converges in higher-risk patients with oesophageal cancer by Rana, M, Sanga, A, Sgromo, B, Gillies, R, Marshall, R, Maynard, N, Ash, S, Antonowicz, S, Owen, R

Attempted validation of the NUn score and inflammatory markers as predictors of esophageal anastomotic leak and major complications by Findlay, J, Tilson, R, Harikrishnan, A, Sgromo, B, Marshall, R, Maynard, N, Gillies, R, Middleton, M

CDX1 is an important molecular mediator of Barrett's metaplasia. by Wong, N, Wilding, J, Bartlett, S, Liu, Y, Warren, B, Piris, J, Maynard, N, Marshall, R, Bodmer, W

Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. by Findlay, J, Bradley, K, Wang, L, Franklin, J, Teoh, E, Gleeson, F, Maynard, N, Gillies, R, Middleton, M

Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery by Findlay, J, Antonowicz, S, Segaran, A, El Kafsi, J, Zhang, A, Bradley, K, Gillies, R, Maynard, N, Middleton, M

Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer. by Gillies, R, Middleton, MR, Blesing, C, Patel, K, Warner, N, Marshall, R, Maynard, N, Bradley, K, Gleeson, F